Global 3D Cell Culture Industry
NEW YORK, Nov. 25, 2020 /PRNewswire/ --
Read the full report: https://www.reportlinker.com/p05797741/?utm_source=PRN
The global market for 3D Cell Culture is projected to reach US$2.3 billion by the year 2027, trailing a post COVID-19 CAGR of 13.7% over the analysis period 2020 through 2027. A 3D-Cell Culture is an artificial environment that allows biological cells to interact with the environment in a three-dimensional manner, similar to cells "in-vivo". Cells in a 3D-cell culture model are subject to similar stimuli and environmental conditions faced by cells in a living organism. The close replication of real-world conditions in 3D-cell culture models have made them increasingly popular in the life-sciences industry. 3D-cell cultures have a range of applications in tissue engineering, drug discovery, gene-expression, disease pathology and developmental biology among other fields. Two common 3D-cell cultures models are Spheroids and Organoids. Spheroids are simple models that are generated from the natural tendency of adherent cells to aggregate. Standard spheroid models are generated from various cell types that result in embryoid bodies, tumor-spheroids, neurospheres, mammospheres and hepatospheres. Spheroids form metabolic gradients that enable them to replicate microenvironments of cells and tissues in diseased states.
3D cell culture allows evolution of cells in an environment very similar to their natural environment. Culturing cell in three dimensions enables the cells to adopt a similar morphological characteristics and migration as found in in-vivo conditions. The recapitulation of the cell's natural morphology is vital as the cell's shape can have a direct impact on their biological activity. Moreover, accurate replication of the cell's migration modes is also important as they form the basis for many diseases, such as cancer. Placement of cells in a 3D configuration significantly enhances their level of interaction with their surroundings, allowing them to interact more strongly with the microenvironment as they would do in a tissue. This is extremely important as recent findings have proved that cell interactions with their microenvironment and extracellular matrix are vital for several cellular functionalities. In addition, the support system in 3D cell culture offers physical as well as biochemical anchorage, which can be altered for replicating in-vivo conditions. Moreover, the pore size or stiffness of the extracellular matrix can be modified for resembling the desired tissue. Further, 3D cell culture also facilitates the formation and evaluation of several complex multi-cellular structures, such as a microvasculature, organoids, or spheroids.
There are various formats of 3D cell culture, which can either be used individually or in combination with others. Some of the common 3D cell culture formats include 3D porous scaffolds, scaffold-free platforms, microchips, hydrogels, and bioreactors. In 3D porous scaffolds, cells are grown inside the pore structures of either naturally-derived fibrous materials, such as laminin or collagen, or engineered scaffolds. Scaffold-free cell culture technique allows cells to self-assemble to form multi-cellular structures with a scaffold support. These multi-cellular structures can be formed on their own, as in case of organoids and spheroids, or through the use of the cell-sheet technology. Cells can also be placed in microchip compartments for forming cellular microenvironments with high structural complexity in close resemblance to organs. Hydrogels are polymeric materials comprising a network of cross-linked polymer chains capable of absorbing and retaining water. Hydrogels can be derived either from animals, plants, or synthesized using chemicals. Bioreactors are defined as hollow cylindrical vessels that can locally control parameters, such as gas exchange, humidity, temperature, and perfusion. During 3D cell culture, bioreactors are often used in combination with scaffolds. In recent years, 3D bioprinting has also emerged as another major 3D cell culture format, enabling layer-by-layer placement of cells and other biological materials in a pre-defined configuration. In addition, there are various companies that offer product customization as per the requirements of researchers.
Competitors identified in this market include, among others,
- 3D Biotek, LLC
- Corning, Inc.
- Emulate, Inc.
- Greiner Bio One International GmbH
- Hamilton Company
- InSphero AG
- Kuraray Co., Ltd.
- Lonza Group AG
- MilliporeSigma
- Mimetas
- QGel SA
- Reprocell, Inc.
- Synthecon
- Thermo Fisher Scientific, Inc.
Read the full report: https://www.reportlinker.com/p05797741/?utm_source=PRN
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1
II. EXECUTIVE SUMMARY II-1
1. MARKET OVERVIEW II-1
3D Cell Culture Transforms Life Sciences Industry II-1
3D Cell Culture: An Introduction II-1
3D-Cell Culture Models II-1
Benefits of 3D Cell Culture II-2
Key 3D Cell Culture Formats II-2
3D Cell Culture?Different Techniques II-2
Scaffold-Based 3D Cell Culture II-3
Polymeric Hard Scaffolds II-3
Biological Scaffolds II-3
Micropatterned Surface Microplates II-4
Non-Scaffold Based 3D Cell Culture II-4
Hanging Drop Microplates II-4
Spheroid Microplates with Ultra-Low Attachment (ULA) coating II-5
Microfluidic 3D Cell Culture II-6
Expanding Applications Fuel Growth in the Global 3D Cell
Culture Market II-6
Developed Regions Lead the 3D Cell Culture Market, Asia-Pacific
to Register Faster Growth II-7
Scaffold-based 3D Cell Culture Products Dominate the Market II-7
Cancer and Stem Cell Research Leads the Global Market II-8
Competitive Scenario II-8
Key Commercial 3D Cell Culture Devices II-8
2. FOCUS ON SELECT PLAYERS II-10
Recent Market Activity II-11
3. MARKET TRENDS & DRIVERS II-12
Rising Incidence of Cancer Drives the Demand for 3D Cell Culture II-12
Exhibit 1: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-12
Exhibit 2: Global Number of New Cancer Cases and Cancer-related
Deaths by Cancer Site for 2018 II-13
Exhibit 3: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018 II-14
Increasing Demand for 3D Cell Culture in Drug Discovery II-14
Use of 3D Cell Culture for Regenerative Medicine II-15
Organoids as Alternatives to Using Animals in Experiments II-15
Use of 3D Cell Culture for Regenerative Medicine II-16
Microfluidic Chips Hold Potential in Addressing 3D Cell Culture
Challenges II-16
Technological Advancements Promote 3D Cell Culture Market II-17
Researchers Use Lab-on-a-CD Technology to Generate Spheroid 3D
Cell Cultures II-18
3D Bioprinting Holds Potential to Revolutionize Organ
Transplantation Space II-19
A Review of Research Efforts and Achievements of Companies and
Universities II-20
3D Tissue Culture: Growing Significance in Cancer Research II-20
Cells Grown in 3D Change Cell Proliferation and Morphology II-21
Cells Grown in 3D Demonstrate a More Pragmatic Drug Response II-22
Cells Grown in 3D Express Phenotypic Heterogeneity II-22
Cells Grown in 3D Alter Cell Behavior and Gene Expression II-22
Cells Grown in 3D Replicate the Tumor Microenvironment II-23
Other Advantages of 3D Tissue Culture Models II-23
New Dimension of Cell Culture: The Rise of Spheroid Culture
Systems II-23
Challenges II-25
Progress in Scaffolds and Hydrogels Aids Creation of Organoids
and Spheroids II-26
4. GLOBAL MARKET PERSPECTIVE II-27
Table 1: World Current & Future Analysis for 3D Cell Culture by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-27
Table 2: World Historic Review for 3D Cell Culture by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2017 through 2019 II-28
Table 3: World 10-Year Perspective for 3D Cell Culture by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2017, 2020 & 2027 II-29
Table 4: World Current & Future Analysis for Scaffold-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-30
Table 5: World Historic Review for Scaffold-based by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2017 through 2019 II-31
Table 6: World 10-Year Perspective for Scaffold-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2017, 2020 & 2027 II-32
Table 7: World Current & Future Analysis for Scaffold-free by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-33
Table 8: World Historic Review for Scaffold-free by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2017 through 2019 II-34
Table 9: World 10-Year Perspective for Scaffold-free by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2017, 2020 & 2027 II-35
Table 10: World Current & Future Analysis for
Microfluidics-based by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-36
Table 11: World Historic Review for Microfluidics-based by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2017 through 2019 II-37
Table 12: World 10-Year Perspective for Microfluidics-based by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2017, 2020 & 2027 II-38
Table 13: World Current & Future Analysis for Magnetic &
Bioprinted by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-39
Table 14: World Historic Review for Magnetic & Bioprinted by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2017 through 2019 II-40
Table 15: World 10-Year Perspective for Magnetic & Bioprinted
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2017, 2020 & 2027 II-41
Table 16: World Current & Future Analysis for Cancer & Stem
Cell Research by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 II-42
Table 17: World Historic Review for Cancer & Stem Cell Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2017 through 2019 II-43
Table 18: World 10-Year Perspective for Cancer & Stem Cell
Research by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2017, 2020 & 2027 II-44
Table 19: World Current & Future Analysis for Drug Discovery &
Toxicology Testing by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-45
Table 20: World Historic Review for Drug Discovery & Toxicology
Testing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2017 through
2019 II-46
Table 21: World 10-Year Perspective for Drug Discovery &
Toxicology Testing by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-47
Table 22: World Current & Future Analysis for Tissue
Engineering & Regenerative Medicine by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-48
Table 23: World Historic Review for Tissue Engineering &
Regenerative Medicine by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2017 through 2019 II-49
Table 24: World 10-Year Perspective for Tissue Engineering &
Regenerative Medicine by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-50
III. MARKET ANALYSIS III-1
GEOGRAPHIC MARKET ANALYSIS III-1
UNITED STATES III-1
Table 25: USA Current & Future Analysis for 3D Cell Culture by
Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-1
Table 26: USA Historic Review for 3D Cell Culture by Product -
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2017 through 2019 III-2
Table 27: USA 10-Year Perspective for 3D Cell Culture by
Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-3
Table 28: USA Current & Future Analysis for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-4
Table 29: USA Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-5
Table 30: USA 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-6
CANADA III-7
Table 31: Canada Current & Future Analysis for 3D Cell Culture
by Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-7
Table 32: Canada Historic Review for 3D Cell Culture by Product -
Scaffold-based, Scaffold-free, Microfluidics-based and
Magnetic & Bioprinted Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 III-8
Table 33: Canada 10-Year Perspective for 3D Cell Culture by
Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-9
Table 34: Canada Current & Future Analysis for 3D Cell Culture
by Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-10
Table 35: Canada Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-11
Table 36: Canada 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-12
JAPAN III-13
Table 37: Japan Current & Future Analysis for 3D Cell Culture
by Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-13
Table 38: Japan Historic Review for 3D Cell Culture by Product -
Scaffold-based, Scaffold-free, Microfluidics-based and
Magnetic & Bioprinted Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 III-14
Table 39: Japan 10-Year Perspective for 3D Cell Culture by
Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-15
Table 40: Japan Current & Future Analysis for 3D Cell Culture
by Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-16
Table 41: Japan Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-17
Table 42: Japan 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-18
CHINA III-19
Table 43: China Current & Future Analysis for 3D Cell Culture
by Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-19
Table 44: China Historic Review for 3D Cell Culture by Product -
Scaffold-based, Scaffold-free, Microfluidics-based and
Magnetic & Bioprinted Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 III-20
Table 45: China 10-Year Perspective for 3D Cell Culture by
Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-21
Table 46: China Current & Future Analysis for 3D Cell Culture
by Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-22
Table 47: China Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-23
Table 48: China 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-24
EUROPE III-25
Table 49: Europe Current & Future Analysis for 3D Cell Culture
by Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 III-25
Table 50: Europe Historic Review for 3D Cell Culture by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-26
Table 51: Europe 10-Year Perspective for 3D Cell Culture by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2017, 2020 & 2027 III-27
Table 52: Europe Current & Future Analysis for 3D Cell Culture
by Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-28
Table 53: Europe Historic Review for 3D Cell Culture by Product -
Scaffold-based, Scaffold-free, Microfluidics-based and
Magnetic & Bioprinted Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 III-29
Table 54: Europe 10-Year Perspective for 3D Cell Culture by
Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-30
Table 55: Europe Current & Future Analysis for 3D Cell Culture
by Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-31
Table 56: Europe Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-32
Table 57: Europe 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-33
FRANCE III-34
Table 58: France Current & Future Analysis for 3D Cell Culture
by Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-34
Table 59: France Historic Review for 3D Cell Culture by Product -
Scaffold-based, Scaffold-free, Microfluidics-based and
Magnetic & Bioprinted Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 III-35
Table 60: France 10-Year Perspective for 3D Cell Culture by
Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-36
Table 61: France Current & Future Analysis for 3D Cell Culture
by Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-37
Table 62: France Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-38
Table 63: France 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-39
GERMANY III-40
Table 64: Germany Current & Future Analysis for 3D Cell Culture
by Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-40
Table 65: Germany Historic Review for 3D Cell Culture by
Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2017 through 2019 III-41
Table 66: Germany 10-Year Perspective for 3D Cell Culture by
Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-42
Table 67: Germany Current & Future Analysis for 3D Cell Culture
by Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-43
Table 68: Germany Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-44
Table 69: Germany 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-45
ITALY III-46
Table 70: Italy Current & Future Analysis for 3D Cell Culture
by Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-46
Table 71: Italy Historic Review for 3D Cell Culture by Product -
Scaffold-based, Scaffold-free, Microfluidics-based and
Magnetic & Bioprinted Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2017 through 2019 III-47
Table 72: Italy 10-Year Perspective for 3D Cell Culture by
Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-48
Table 73: Italy Current & Future Analysis for 3D Cell Culture
by Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-49
Table 74: Italy Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-50
Table 75: Italy 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-51
UNITED KINGDOM III-52
Table 76: UK Current & Future Analysis for 3D Cell Culture by
Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 III-52
Table 77: UK Historic Review for 3D Cell Culture by Product -
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2017 through 2019 III-53
Table 78: UK 10-Year Perspective for 3D Cell Culture by Product -
Percentage Breakdown of Value Sales for Scaffold-based,
Scaffold-free, Microfluidics-based and Magnetic & Bioprinted
for the Years 2017, 2020 & 2027 III-54
Table 79: UK Current & Future Analysis for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-55
Table 80: UK Historic Review for 3D Cell Culture by Application -
Cancer & Stem Cell Research, Drug Discovery & Toxicology
Testing and Tissue Engineering & Regenerative Medicine Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2017 through 2019 III-56
Table 81: UK 10-Year Perspective for 3D Cell Culture by
Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
2020 & 2027 III-57
REST OF EUROPE III-58
Table 82: Rest of Europe Current & Future Analysis for 3D Cell
Culture by Product - Scaffold-based, Scaffold-free,
Microfluidics-based and Magnetic & Bioprinted - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-58
Table 83: Rest of Europe Historic Review for 3D Cell Culture by
Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2017 through 2019 III-59
Table 84: Rest of Europe 10-Year Perspective for 3D Cell
Culture by Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-60
Table 85: Rest of Europe Current & Future Analysis for 3D Cell
Culture by Application - Cancer & Stem Cell Research, Drug
Discovery & Toxicology Testing and Tissue Engineering &
Regenerative Medicine - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-61
Table 86: Rest of Europe Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-62
Table 87: Rest of Europe 10-Year Perspective for 3D Cell
Culture by Application - Percentage Breakdown of Value Sales
for Cancer & Stem Cell Research, Drug Discovery & Toxicology
Testing and Tissue Engineering & Regenerative Medicine for the
Years 2017, 2020 & 2027 III-63
ASIA-PACIFIC III-64
Table 88: Asia-Pacific Current & Future Analysis for 3D Cell
Culture by Product - Scaffold-based, Scaffold-free,
Microfluidics-based and Magnetic & Bioprinted - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-64
Table 89: Asia-Pacific Historic Review for 3D Cell Culture by
Product - Scaffold-based, Scaffold-free, Microfluidics-based
and Magnetic & Bioprinted Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2017 through 2019 III-65
Table 90: Asia-Pacific 10-Year Perspective for 3D Cell Culture
by Product - Percentage Breakdown of Value Sales for
Scaffold-based, Scaffold-free, Microfluidics-based and Magnetic &
Bioprinted for the Years 2017, 2020 & 2027 III-66
Table 91: Asia-Pacific Current & Future Analysis for 3D Cell
Culture by Application - Cancer & Stem Cell Research, Drug
Discovery & Toxicology Testing and Tissue Engineering &
Regenerative Medicine - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-67
Table 92: Asia-Pacific Historic Review for 3D Cell Culture by
Application - Cancer & Stem Cell Research, Drug Discovery &
Toxicology Testing and Tissue Engineering & Regenerative
Medicine Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2017 through 2019 III-68
Table 93: Asia-Pacific 10-Year Perspective for 3D Cell Culture
by Application - Percentage Breakdown of Value Sales for Cancer &
Stem Cell Research, Drug Discovery & Toxicology Testing and
Tissue Engineering & Regenerative Medicine for the Years 2017,
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05797741/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: +(339)-368-6001
Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/global-3d-cell-culture-industry-301180501.html
SOURCE Reportlinker